A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.
1 other identifier
interventional
24
1 country
1
Brief Summary
Dopamine (DA) plays a critical role in nicotine (and other) addiction and this drug is known to release DA in brain areas mediating reward and motivational processes. Although imaging studies show that release of DA follows smoking, little is known regarding how common genetic polymorphisms for three genes associated in some studies with smoking (dopamine D2 receptor, dopamine and serotonin transporter) interact with smoking status and modulate individual differences in nicotine-induced DA release and dopamine receptor occupancy, in vivo. The current proposal combines brain imaging and genomics ('imaging genomics') towards partially unraveling the complex relationship between smoking phenotype and common polymorphisms. Understanding whether genetic factors contribute to inter-individual variability in smoking is crucial for interpreting imaging results in the context of disease pathology. We hypothesize that a model of vulnerability to addiction based on interactions between genotype, receptor and transporter availability and in vivo nicotine-induced DA release will elucidate some of the fundamental neurochemical and neurogenetic circuits underlying addiction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2007
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 6, 2006
CompletedFirst Posted
Study publicly available on registry
November 7, 2006
CompletedStudy Start
First participant enrolled
July 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2012
CompletedMarch 27, 2012
March 1, 2012
5 years
November 6, 2006
March 26, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Dopamine D2 receptor occupancy before and after smoking a cigarette with nicotine
30 minutes
Secondary Outcomes (1)
Subjective measures of craving, anxiety and depression.
30 minutes
Study Arms (1)
Dopamine release
EXPERIMENTALInterventions
We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
Eligibility Criteria
You may qualify if:
- smokers who smoked 15 cigarettes/day and who met the DSM-IV criteria for nicotine dependence
You may not qualify if:
- Subjects who are diagnosed as suffering from psychotic illness according to DSM-IV (Axis 1)22, or with a history of CNS disease, a history of infection that might affect CNS (HIV, syphilis, cytomegalovirus, herpes), or a history of head injury with loss of consciousness will be excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hadassah Medical Organization
Jerusalem, 91120, Israel
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Aviv M Weinstein, Ph.D
Hadassah Medical Organization
- PRINCIPAL INVESTIGATOR
Moshe Bocher, M.D
Hadassah Medical Organization
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior Research Fellow
Study Record Dates
First Submitted
November 6, 2006
First Posted
November 7, 2006
Study Start
July 1, 2007
Primary Completion
July 1, 2012
Study Completion
July 1, 2012
Last Updated
March 27, 2012
Record last verified: 2012-03